Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Celyad Oncology SA

Celyad Oncology announces intention to terminate SEC reporting obligations
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
From Celyad Oncology SA
Via GlobeNewswire
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Celyad announces management change
From Celyad Oncology SA
Via GlobeNewswire
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology announces the termination of its American Depository Receipt program
From Celyad Oncology SA
Via GlobeNewswire
Publication of a rectified transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology announces receipt of Nasdaq delisting notice
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology announces receipt of Nasdaq notice
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology appoints Georges Rawadi as its new CEO
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology reports full year 2022 financial results and recent business highlights
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology to announce full year 2022 financial results and host conference call
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology announces non-cash impairment
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
REPEAT -- Celyad Oncology SA - Letter to Shareholders
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology SA - Letter to Shareholders
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
From Celyad Oncology SA
Via GlobeNewswire
Tickers CYAD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.